tiprankstipranks
Trending News
More News >
Prothena (PRTA)
NASDAQ:PRTA
Advertisement

Prothena (PRTA) AI Stock Analysis

Compare
667 Followers

Top Page

PRTA

Prothena

(NASDAQ:PRTA)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 4o)
Rating:53Neutral
Price Target:
$10.50
▼(-1.41% Downside)
Prothena's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and negative profit margins. Despite these challenges, the stock shows positive technical momentum, which provides some optimism. However, the negative P/E ratio and lack of dividend yield weigh down the valuation score, reflecting ongoing profitability issues.
Positive Factors
Strategic Partnerships
Prothena's partnership with Bristol Myers Squibb, including potential milestone payments, enhances its financial prospects and supports long-term growth.
Regulatory Progress
The Fast Track Designation for BMS-986446 accelerates its development, potentially leading to faster market entry and revenue generation for Prothena.
Pipeline Advancement
Advancing coramitug into Phase 3 with Novo Nordisk signifies progress in Prothena's pipeline, indicating potential future revenue streams and market impact.
Negative Factors
Declining Revenue
Significant revenue decline poses a challenge to Prothena's financial stability and may hinder its ability to fund ongoing R&D and operational activities.
Negative Profit Margins
Sustained negative profit margins indicate ongoing profitability challenges, potentially impacting Prothena's ability to invest in growth and innovation.
Cash Flow Challenges
Negative cash flows highlight liquidity issues, limiting Prothena's financial flexibility and potentially affecting its long-term operational capabilities.

Prothena (PRTA) vs. SPDR S&P 500 ETF (SPY)

Prothena Business Overview & Revenue Model

Company DescriptionProthena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
How the Company Makes MoneyProthena generates revenue through a combination of collaborations, licensing agreements, and potential milestone payments from its partnerships with pharmaceutical companies. The company enters into strategic alliances with larger biopharmaceutical firms that provide upfront payments and ongoing funding to support the development of its drug candidates. Additionally, Prothena may receive royalties on product sales if its partnered therapies reach the market. The company also has the potential for milestone payments as its candidates progress through various stages of clinical development, thereby contributing significantly to its earnings.

Prothena Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how much revenue each business segment generates, highlighting which parts of the company are driving growth and which may need strategic adjustments.
Chart InsightsProthena's revenue from the Collaboration segment has experienced significant volatility, with notable spikes in mid-2021 and mid-2024. This suggests strategic partnerships or milestone payments driving revenue surges. Meanwhile, the License and Intellectual Property segment remains inconsistent, with occasional large contributions, likely from one-time licensing deals. The absence of recent earnings commentary leaves the sustainability of these revenue streams uncertain, highlighting potential risks for investors relying on consistent growth.
Data provided by:Main Street Data

Prothena Earnings Call Summary

Earnings Call Date:Oct 30, 2025
(Q4-2024)
|
% Change Since: |
Next Earnings Date:Feb 12, 2026
Earnings Call Sentiment Neutral
The earnings call presents a balanced outlook for Prothena. While there are significant opportunities for growth through its robust portfolio and strategic partnerships, challenges remain, particularly with the dependency on future clinical trial successes and the narrow miss in prasinezumab's statistical significance.
Q4-2024 Updates
Positive Updates
Robust Portfolio and Strategic Partnerships
Prothena has a robust portfolio with four wholly-owned and four partnered programs across various stages of clinical development, allowing strategic collaborations to advance treatments while maintaining financial benefits.
Birtamimab's Commercial Potential
Birtamimab represents a significant multi-billion dollar global commercial opportunity as the first potential treatment for AL amyloidosis with demonstrated early survival benefit.
Partnerships with Major Pharmaceutical Companies
Collaborations with companies like Roche, Novo Nordisk, and Bristol Myers Squibb enhance the development of prasinezumab, coramitug, and BMS-986446, advancing them as potential transformative treatments.
Strong Financial Position
Prothena ended 2024 with $472.2 million in cash, cash equivalents, and restricted cash, maintaining a simple capital structure with zero debt.
Negative Updates
Prasinezumab Narrowly Misses Statistical Significance
In the Phase 2b PADOVA study for early Parkinson's disease, prasinezumab showed potential but narrowly missed statistical significance with a p-value of 0.0657.
High Dependency on Future Clinical Success
Financial guidance for 2025 is heavily reliant on the success of upcoming clinical trials, with a projected net loss between $197 million and $205 million.
Company Guidance
During the Prothena Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided guidance for 2025, highlighting several key metrics. Prothena expects full-year 2025 net cash used in operating and investing activities to range between $168 million and $175 million, anticipating a year-end cash balance of approximately $301 million. The projected net loss for 2025 is estimated to be between $197 million and $205 million, inclusive of an estimated $41 million in non-cash share-based compensation expense. As of December 31, 2024, Prothena reported $472.2 million in cash, cash equivalents, and restricted cash, and as of February 20, 2025, the company had approximately 53.8 million ordinary shares outstanding. The company emphasized that it maintains a simple capital structure with zero debt.

Prothena Financial Statement Overview

Summary
Prothena shows revenue growth, but persistent losses and cash burn are significant concerns. The company maintains a strong equity position and cash reserves, yet ongoing negative profitability metrics and cash flow issues present risks. Improving profitability is essential for long-term sustainability.
Income Statement
30
Negative
Prothena's revenue has shown growth over the years, with a notable increase from 2020 to 2025. However, the company is currently operating at a loss as evidenced by negative EBIT and net income. Gross profit margin is positive, indicating some operational efficiency, but the net profit margin is negative, highlighting ongoing profitability challenges.
Balance Sheet
45
Neutral
The company's balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, leading to a favorable debt-to-equity ratio. The equity ratio is high, indicating financial stability. However, the return on equity is negative due to persistent net losses, which is a concern for investors.
Cash Flow
35
Negative
Prothena's cash flow situation is challenging with negative operating and free cash flow, suggesting cash burn. The operating cash flow to net income ratio is negative due to ongoing losses, but the company has maintained a decent cash reserve, which provides some buffer.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.34M135.16M91.37M53.91M200.58M853.00K
Gross Profit9.43M135.16M-129.20M47.16M118.29M-74.03M
EBITDA-248.10M-154.56M-190.11M-131.56M71.97M-111.22M
Net Income-302.92M-122.31M-147.03M-116.95M66.97M-111.14M
Balance Sheet
Total Assets399.07M547.11M696.38M758.03M609.37M332.98M
Cash, Cash Equivalents and Short-Term Investments371.44M471.39M618.83M710.41M579.09M295.38M
Total Debt9.78M10.84M11.84M6.47M12.33M17.84M
Total Liabilities74.73M60.18M135.02M135.99M143.32M148.97M
Stockholders Equity324.33M486.93M561.37M622.04M466.04M184.01M
Cash Flow
Free Cash Flow-196.69M-150.35M-136.72M-109.28M92.03M-80.56M
Operating Cash Flow-196.74M-150.05M-133.91M-108.82M92.61M-80.36M
Investing Cash Flow-184.94K-298.00K-2.77M-464.00K-575.00K-196.00K
Financing Cash Flow147.29K1.55M45.10M241.46M190.33M215.00K

Prothena Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10.65
Price Trends
50DMA
9.22
Positive
100DMA
7.90
Positive
200DMA
9.62
Positive
Market Momentum
MACD
0.33
Positive
RSI
63.36
Neutral
STOCH
51.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTA, the sentiment is Positive. The current price of 10.65 is above the 20-day moving average (MA) of 10.17, above the 50-day MA of 9.22, and above the 200-day MA of 9.62, indicating a bullish trend. The MACD of 0.33 indicates Positive momentum. The RSI at 63.36 is Neutral, neither overbought nor oversold. The STOCH value of 51.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTA.

Prothena Risk Analysis

Prothena disclosed 62 risk factors in its most recent earnings report. Prothena reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Prothena Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$483.32M-3.99-65.30%1504.83%56.81%
$568.09M-186.033.53%158.57%96.76%
$573.29M-1.89-66.85%-95.24%-493.05%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
$420.53M-22.55-12.42%194.98%38.01%
$490.14M-66.35%-25.20%
$572.27M-68.67%-50.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRTA
Prothena
10.65
-6.35
-37.35%
LXRX
Lexicon Pharmaceuticals
1.33
-0.62
-31.79%
XOMA
Xoma
33.34
3.14
10.40%
ZVRA
Zevra Therapeutics
10.12
1.97
24.17%
CRVS
Corvus Pharmaceuticals
7.68
-1.16
-13.12%
ALMS
Alumis Inc.
4.71
-6.61
-58.39%

Prothena Corporate Events

Business Operations and StrategyProduct-Related Announcements
Prothena Announces Promising Phase 1 Results for PRX012
Positive
Aug 27, 2025

On August 27, 2025, Prothena announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012, aimed at treating early symptomatic Alzheimer’s disease. The study demonstrated that PRX012, a once-monthly, subcutaneous anti-amyloid beta antibody, showed promising results in reducing amyloid plaque but had higher ARIA-E rates compared to FDA-approved antibodies. Prothena plans to seek partnerships to further develop PRX012 and its preclinical PRX012-TfR antibody, which may offer a reduced risk of ARIA and quicker amyloid plaque reduction.

The most recent analyst rating on (PRTA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk
Positive
Aug 6, 2025

On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with cardiomyopathy. This decision follows the successful completion of a Phase 2 trial and is expected to commence in 2025. Prothena stands to earn a clinical milestone payment upon meeting specific enrollment criteria in the Phase 3 trial. The advancement of coramitug marks a significant step in addressing the unmet needs of patients with ATTR amyloidosis, potentially enhancing Prothena’s industry positioning and offering substantial financial benefits through its agreement with Novo Nordisk.

The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Prothena Reports Q2 2025 Financial Results and Pipeline Progress
Aug 5, 2025

Prothena Corporation plc is a biotechnology company specializing in the development of therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. In its latest earnings report, Prothena highlighted significant advancements in its pipeline, including the progression of prasinezumab into Phase 3 trials for Parkinson’s disease and the upcoming release of initial data from the Phase 1 ASCENT clinical trials for Alzheimer’s treatment PRX012. Financially, Prothena reported a net loss of $125.8 million for the second quarter of 2025, attributed to restructuring charges and a non-cash income tax expense, with total revenue significantly lower than the previous year due to reduced collaboration revenue. The company maintains a strong cash position of $372.3 million, with expectations to end the year with approximately $298 million. Looking ahead, Prothena plans to convene an Extraordinary General Meeting by year-end to propose a share capital reduction, potentially enabling a share redemption program, while continuing to advance its clinical programs and collaborations.

Business Operations and StrategyExecutive/Board Changes
Prothena Secures Leadership with New Executive Agreements
Positive
Jul 30, 2025

On July 30, 2025, Prothena Biosciences Inc entered into employment agreements with key executives, including the Chief Strategy Officer, Chief Operating Officer, and Chief Scientific Officer. These agreements outline their base salaries, bonus opportunities, and severance benefits, which align with the company’s existing severance plan. The agreements provide for enhanced severance benefits in the event of termination without cause or resignation for good reason, with further increases if such termination occurs in connection with a change in control. This move is likely to impact the company’s operations by securing leadership stability and potentially positioning the company more favorably in the industry.

The most recent analyst rating on (PRTA) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025